NAFTIDROFURYL USE IN MODERATE VASCULAR COGNITIVE DISORDERS

Abstract

Prevention of progression to moderate vascular cognitive disorders (MVCD) in dementia is based on medicinal and nonmedicinal correction of major cardiovascular risk factors, at the same time antidementia, vasoactive and nootropic drugs efficiency is not proven. The own experience of use in 30 patients (22 women and 8 men) with MVCD in age from 46 to 75 years (mean age 67,1 ± 6.6 years) of Naftidrofuryl (Duzofarm) at a dose of 100 mg three times a day for 30 days is provided. After a month of treatment a significant improvement of cognitive function by the Montreal scale assessment of mental functions, the alpha-numeric coding test, and emotional state test is established as measured by the hospital scale of anxiety and depression. Good tolerability, absence of significant side effects when using Naftidrofuryl for MVCD are observed. Longer placebo-controlled studies of the effectiveness of Naftidrofuryl in patients with MVCD are needed.

Keywords

• vascular cognitive disorder
• moderate cognitive disorders
• chronic cerebral ischemia
• discirculatory encephalopathy
• naftidrofuryl
• duzofarm